Literature DB >> 18454150

A critical function for transforming growth factor-beta, interleukin 23 and proinflammatory cytokines in driving and modulating human T(H)-17 responses.

Elisabetta Volpe1, Nicolas Servant, Raphaël Zollinger, Sofia I Bogiatzi, Philippe Hupé, Emmanuel Barillot, Vassili Soumelis.   

Abstract

Interleukin 17 (IL-17)-producing T helper 17 cells (T(H)-17 cells) have been described as a T helper cell subset distinct from T helper type 1 (T(H)1) and T(H)2 cells, with specific functions in antimicrobial defense and autoimmunity. The factors driving human T(H)-17 differentiation remain controversial. Using a systematic approach combining experimental and computational methods, we show here that transforming growth factor-beta, interleukin 23 (IL-23) and proinflammatory cytokines (IL-1beta and IL-6) were all essential for human T(H)-17 differentiation. However, individual T(H)-17 cell-derived cytokines, such as IL-17, IL-21, IL-22 and IL-6, as well as the global T(H)-17 cytokine profile, were differentially modulated by T(H)-17-promoting cytokines. Transforming growth factor-beta was critical, and its absence induced a shift from a T(H)-17 profile to a T(H)1-like profile. Our results shed new light on the regulation of human T(H)-17 differentiation and provide a framework for the global analysis of T helper responses.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18454150     DOI: 10.1038/ni.1613

Source DB:  PubMed          Journal:  Nat Immunol        ISSN: 1529-2908            Impact factor:   25.606


  346 in total

Review 1.  T cells: critical bone regulators in health and disease.

Authors:  Roberto Pacifici
Journal:  Bone       Date:  2010-05-07       Impact factor: 4.398

Review 2.  Role of Th17 cells and IL-17 in lung transplant rejection.

Authors:  Rebecca A Shilling; David S Wilkes
Journal:  Semin Immunopathol       Date:  2011-02-01       Impact factor: 9.623

3.  Depletion of antigen-presenting cells by clodronate liposomes reverses the psoriatic skin phenotype in KC-Tie2 mice.

Authors:  N L Ward; C M Loyd; J A Wolfram; D Diaconu; C M Michaels; T S McCormick
Journal:  Br J Dermatol       Date:  2011-04       Impact factor: 9.302

Review 4.  Up for Mischief? IL-17/Th17 in the tumour microenvironment.

Authors:  E Maniati; R Soper; T Hagemann
Journal:  Oncogene       Date:  2010-08-23       Impact factor: 9.867

5.  IL-17-producing human peripheral regulatory T cells retain suppressive function.

Authors:  Gaëlle Beriou; Cristina M Costantino; Charles W Ashley; Li Yang; Vijay K Kuchroo; Clare Baecher-Allan; David A Hafler
Journal:  Blood       Date:  2009-01-26       Impact factor: 22.113

6.  JQ1, a bromodomain inhibitor, suppresses Th17 effectors by blocking p300-mediated acetylation of RORγt.

Authors:  Xiunan Wang; Yan Yang; Dandan Ren; Yuanyuan Xia; Wenguang He; Qingsi Wu; Junling Zhang; Miao Liu; Yinan Du; Cuiping Ren; Bin Li; Jijia Shen; Yuxia Zhang
Journal:  Br J Pharmacol       Date:  2020-03-23       Impact factor: 8.739

Review 7.  Pro- and anti-inflammatory cytokines in cutaneous leishmaniasis: a review.

Authors:  Nahid Maspi; Amir Abdoli; Fathemeh Ghaffarifar
Journal:  Pathog Glob Health       Date:  2016-09-23       Impact factor: 2.894

Review 8.  Regulation and function of proinflammatory TH17 cells.

Authors:  Gustavo J Martinez; Roza I Nurieva; Xuexian O Yang; Chen Dong
Journal:  Ann N Y Acad Sci       Date:  2008-11       Impact factor: 5.691

9.  Tyrosine Kinase 2-mediated Signal Transduction in T Lymphocytes Is Blocked by Pharmacological Stabilization of Its Pseudokinase Domain.

Authors:  John S Tokarski; Adriana Zupa-Fernandez; Jeffrey A Tredup; Kristen Pike; ChiehYing Chang; Dianlin Xie; Lihong Cheng; Donna Pedicord; Jodi Muckelbauer; Stephen R Johnson; Sophie Wu; Suzanne C Edavettal; Yang Hong; Mark R Witmer; Lisa L Elkin; Yuval Blat; William J Pitts; David S Weinstein; James R Burke
Journal:  J Biol Chem       Date:  2015-03-11       Impact factor: 5.157

10.  Treating a Multidrug-Resistant Psoriatic HLA-C*18:01 Allele Carrier with Combination Ustekinumab Apremilast Therapy.

Authors:  Marco Galluzzo; Simone D'Adamio; Elena Campione; Luca Bianchi; Marina Talamonti
Journal:  Mol Diagn Ther       Date:  2018-12       Impact factor: 4.074

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.